Diamond Drugs, Inc.

Form 483 issued July 21, 2017 · Indiana, Pennsylvania

Inspection
Jul 18 – Jul 21, 2017
Investigator
Nancy F. Scheraga
Observations
2
Pages
1
FEI number
3013075945

In short: On July 21, 2017, FDA issued a Form 483 with 2 observations to Diamond Drugs, Inc. in Indiana, Pennsylvania (FEI 3013075945) after an inspection that ran Jul 18 – Jul 21, 2017. The investigator was Nancy F. Scheraga. Most observations concern production; the most-cited regulation is 21 CFR 211.113 (control of microbiological contamination).

At a glance

2 of 2 observations on this 483 concern production.

Production2

Most cited: 21 CFR 211.113 (2×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    The ISO 5 laminar air flow hood was not…

  2. 02

    Disinfecting agents used in the ISO 5 laminar air flow…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Diamond Drugs, Inc.?

FDA listed 2 observations on this Form 483, mostly about production. The most-cited regulation is 21 CFR 211.113 (control of microbiological contamination). The opening words of each observation are shown on this page.

Who inspected Diamond Drugs, Inc.?

Nancy F. Scheraga is named on this Form 483, for the inspection of Jul 18 – Jul 21, 2017. Each investigator has a profile showing what they cite most.

When was Diamond Drugs, Inc. inspected by FDA?

The inspection ran Jul 18 – Jul 21, 2017, and the Form 483 is dated July 21, 2017.

How do I get the full Form 483 for Diamond Drugs, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free